{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:57:29Z","timestamp":1785344249958,"version":"3.55.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04289-6","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:13:16Z","timestamp":1772187196000},"page":"3042-3058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unravelling the pathogenesis and therapeutic approaches of pancreatic ductal adenocarcinoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Isha","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-4090","authenticated-orcid":false,"given":"Raman","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"4289_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.Can-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913\u201321. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-0155.","journal-title":"Cancer Res"},{"key":"4289_CR2","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3748\/wjg.v27.i23.3158","volume":"27","author":"N Gupta","year":"2021","unstructured":"Gupta N, Yelamanchi R. Pancreatic adenocarcinoma: a review of recent paradigms and advances in epidemiology, clinical diagnosis and management. World J Gastroenterol. 2021;27:3158\u201381. https:\/\/doi.org\/10.3748\/wjg.v27.i23.3158.","journal-title":"World J Gastroenterol"},{"key":"4289_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00534-006-1166-5","volume":"14","author":"G Feldmann","year":"2007","unstructured":"Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg. 2007;14:224\u201332. https:\/\/doi.org\/10.1007\/s00534-006-1166-5.","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"4289_CR4","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846\u201361. https:\/\/doi.org\/10.3748\/wjg.v24.i43.4846.","journal-title":"World J Gastroenterol"},{"key":"4289_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/SLA.0b013e31825ffbfb","volume":"257","author":"KE Poruk","year":"2013","unstructured":"Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg. 2013;257:17\u201326. https:\/\/doi.org\/10.1097\/SLA.0b013e31825ffbfb.","journal-title":"Ann Surg"},{"key":"4289_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000017175","volume":"98","author":"X Pei","year":"2019","unstructured":"Pei X, Song F, Wang Z. Emerging incidence trends and application of curative treatments of pancreatic cancer in the USA. Medicine (Baltimore). 2019;98:e17175. https:\/\/doi.org\/10.1097\/md.0000000000017175.","journal-title":"Medicine (Baltimore)"},{"key":"4289_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70318","volume":"13","author":"Z Hesami","year":"2024","unstructured":"Hesami Z, Olfatifar M, Sadeghi A, Zali MR, Mohammadi-Yeganeh S, Habibi MA, et al. Global trend in pancreatic cancer prevalence rates through 2040: an illness-death modeling study. Cancer Med. 2024;13:e70318. https:\/\/doi.org\/10.1002\/cam4.70318.","journal-title":"Cancer Med"},{"key":"4289_CR8","doi-asserted-by":"publisher","first-page":"11182","DOI":"10.3748\/wjg.v20.i32.11182","volume":"20","author":"AE Becker","year":"2014","unstructured":"Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014;20:11182\u201398. https:\/\/doi.org\/10.3748\/wjg.v20.i32.11182.","journal-title":"World J Gastroenterol"},{"key":"4289_CR9","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2903101","volume":"29","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Pawlik TM. Molecular classification and pathogenesis of pancreatic adenocarcinoma and targeted therapies: a review. Front Biosci-Landmark. 2024;29:101. https:\/\/doi.org\/10.31083\/j.fbl2903101.","journal-title":"Front Biosci-Landmark"},{"key":"4289_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000178874","volume":"9","author":"B Sipos","year":"2009","unstructured":"Sipos B, Frank S, Gress T, Hahn S, Kl\u00f6ppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology. 2009;9:45\u201354. https:\/\/doi.org\/10.1159\/000178874.","journal-title":"Pancreatology"},{"key":"4289_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","volume":"48","author":"J Luo","year":"2021","unstructured":"Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021;48:10\u20138. https:\/\/doi.org\/10.1053\/j.seminoncol.2021.02.003.","journal-title":"Semin Oncol"},{"key":"4289_CR12","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8643","author":"J Zhang","year":"2023","unstructured":"Zhang J, Darman L, Hassan MS, Von Holzen U, Awasthi N. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: recent advancements provide hope (Review). Oncol Rep. 2023. https:\/\/doi.org\/10.3892\/or.2023.8643.","journal-title":"Oncol Rep"},{"key":"4289_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02473-8","volume":"10","author":"K Choucair","year":"2025","unstructured":"Choucair K, Imtiaz H, Uddin MH, Nagasaka M, Al-Hallak MN, Philip PA, et al. Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. Signal Transduct Target Ther. 2025;10:385. https:\/\/doi.org\/10.1038\/s41392-025-02473-8.","journal-title":"Signal Transduct Target Ther"},{"key":"4289_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10555-021-09990-2","volume":"40","author":"SF Bannoura","year":"2021","unstructured":"Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021;40:819\u201335. https:\/\/doi.org\/10.1007\/s10555-021-09990-2.","journal-title":"Cancer Metastasis Rev"},{"key":"4289_CR15","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cimb46040177","volume":"46","author":"D Stefanoudakis","year":"2024","unstructured":"Stefanoudakis D, Frountzas M, Schizas D, Michalopoulos NV, Drakaki A, Toutouzas KG. Significance of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer. Curr Issues Mol Biol. 2024;46:2827\u201344. https:\/\/doi.org\/10.3390\/cimb46040177.","journal-title":"Curr Issues Mol Biol"},{"key":"4289_CR16","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.2147\/cmar.S211151","volume":"12","author":"W Wong","year":"2020","unstructured":"Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects. Cancer Manag Res. 2020;12:2731\u201342. https:\/\/doi.org\/10.2147\/cmar.S211151.","journal-title":"Cancer Manag Res"},{"key":"4289_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.stem.2021.03.005","volume":"28","author":"M Breunig","year":"2021","unstructured":"Breunig M, Merkle J, Wagner M, Melzer MK, Barth TFE, Engleitner T, et al. Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells. Cell Stem Cell. 2021;28:1105-1124.e1119. https:\/\/doi.org\/10.1016\/j.stem.2021.03.005.","journal-title":"Cell Stem Cell"},{"key":"4289_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710132","author":"S Stanciu","year":"2022","unstructured":"Stanciu S, Ionita-Radu F, Stefani C, Miricescu D, Stanescu S II, Greabu M, et al. Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231710132.","journal-title":"Int J Mol Sci"},{"key":"4289_CR19","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/med.21802","volume":"41","author":"SW Hung","year":"2021","unstructured":"Hung SW, Zhang R, Tan Z, Chung JPW, Zhang T, Wang CC. Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: a review. Med Res Rev. 2021;41:2489\u2013564. https:\/\/doi.org\/10.1002\/med.21802.","journal-title":"Med Res Rev"},{"key":"4289_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5732\/cjc.013.10057","volume":"32","author":"KH Khan","year":"2013","unstructured":"Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer. 2013;32:253\u201365. https:\/\/doi.org\/10.5732\/cjc.013.10057.","journal-title":"Chin J Cancer"},{"key":"4289_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1593\/neo.12532","volume":"14","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Sun Y. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia. 2012;14:360\u20137. https:\/\/doi.org\/10.1593\/neo.12532.","journal-title":"Neoplasia"},{"key":"4289_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2174\/0929867324666170206142658","volume":"24","author":"S Ebrahimi","year":"2017","unstructured":"Ebrahimi S, Hosseini M, Shahidsales S, Maftouh M, Ferns GA, Ghayour-Mobarhan M, et al. Targeting the Akt\/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. Curr Med Chem. 2017;24:1321\u201331. https:\/\/doi.org\/10.2174\/0929867324666170206142658.","journal-title":"Curr Med Chem"},{"key":"4289_CR23","doi-asserted-by":"publisher","first-page":"10123","DOI":"10.1158\/0008-5472.Can-07-3127","volume":"67","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67:10123\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-3127.","journal-title":"Cancer Res"},{"key":"4289_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1245\/s10434-014-4046-2","volume":"22","author":"T Yamamoto","year":"2015","unstructured":"Yamamoto T, Sugiura T, Mizuno T, Okamura Y, Aramaki T, Endo M, et al. Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:677\u201384. https:\/\/doi.org\/10.1245\/s10434-014-4046-2.","journal-title":"Ann Surg Oncol"},{"key":"4289_CR25","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1172\/jci69600","volume":"123","author":"CT Hensley","year":"2013","unstructured":"Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678\u201384. https:\/\/doi.org\/10.1172\/jci69600.","journal-title":"J Clin Invest"},{"key":"4289_CR26","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.071152","volume":"34","author":"D Cai","year":"2025","unstructured":"Cai D, Ji J, Yang C, Cai H. Branched-chain amino acid metabolic reprogramming and cancer: molecular mechanisms, immune regulation, and precision targeting. Oncol Res. 2025;34:9. https:\/\/doi.org\/10.32604\/or.2025.071152.","journal-title":"Oncol Res"},{"key":"4289_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0350-z","volume":"51","author":"JH Lee","year":"2019","unstructured":"Lee JH, Cho YR, Kim JH, Kim J, Nam HY, Kim SW, et al. Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolism. Exp Mol Med. 2019;51:1\u201311. https:\/\/doi.org\/10.1038\/s12276-019-0350-z.","journal-title":"Exp Mol Med"},{"key":"4289_CR28","doi-asserted-by":"publisher","first-page":"798S","DOI":"10.3945\/an.115.011221","volume":"7","author":"EA Ananieva","year":"2016","unstructured":"Ananieva EA, Powell JD, Hutson SM. Leucine metabolism in T cell activation: mTOR signaling and beyond. Adv Nutr. 2016;7:798S-805S. https:\/\/doi.org\/10.3945\/an.115.011221.","journal-title":"Adv Nutr"},{"key":"4289_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41556-019-0455-6","volume":"22","author":"JT Li","year":"2020","unstructured":"Li JT, Yin M, Wang D, Wang J, Lei MZ, Zhang Y, et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat Cell Biol. 2020;22:167\u201374. https:\/\/doi.org\/10.1038\/s41556-019-0455-6.","journal-title":"Nat Cell Biol"},{"key":"4289_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101599","author":"F Glapi\u0144ski","year":"2025","unstructured":"Glapi\u0144ski F, Zaj\u0105c W, Fudalej M, Depta\u0142a A, Czerw A, Sygit K, et al. The role of the tumor microenvironment in pancreatic ductal adenocarcinoma: recent advancements and emerging therapeutic strategies. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17101599.","journal-title":"Cancers"},{"key":"4289_CR31","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3748\/wjg.v28.i27.3297","volume":"28","author":"C Smith","year":"2022","unstructured":"Smith C, Zheng W, Dong J, Wang Y, Lai J, Liu X, et al. Tumor microenvironment in pancreatic ductal adenocarcinoma: implications in immunotherapy. World J Gastroenterol. 2022;28:3297\u2013313. https:\/\/doi.org\/10.3748\/wjg.v28.i27.3297.","journal-title":"World J Gastroenterol"},{"key":"4289_CR32","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.Ccr-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21:3561\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1051.","journal-title":"Clin Cancer Res"},{"key":"4289_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418\u201329. https:\/\/doi.org\/10.1016\/j.ccr.2012.01.007.","journal-title":"Cancer Cell"},{"key":"4289_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1586\/17474124.2016.1117386","volume":"10","author":"M Erkan","year":"2016","unstructured":"Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol. 2016;10:301\u201316. https:\/\/doi.org\/10.1586\/17474124.2016.1117386.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4289_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbcan.2018.07.002","volume":"1870","author":"D Samanta","year":"2018","unstructured":"Samanta D, Semenza GL. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. Biochim Biophys Acta (BBA) Rev Cancer. 2018;1870:15\u201322. https:\/\/doi.org\/10.1016\/j.bbcan.2018.07.002.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"key":"4289_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041235","author":"R Abou Khouzam","year":"2023","unstructured":"Abou Khouzam R, Lehn JM, Mayr H, Clavien PA, Wallace MB, Ducreux M, et al. Hypoxia, a targetable culprit to counter pancreatic cancer resistance to therapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041235.","journal-title":"Cancers (Basel)"},{"key":"4289_CR37","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.3892\/ol.2019.10956","volume":"18","author":"X Ke","year":"2019","unstructured":"Ke X, Chen C, Song Y, Cai Q, Li J, Tang Y, et al. Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells. Oncol Lett. 2019;18:5871\u20138. https:\/\/doi.org\/10.3892\/ol.2019.10956.","journal-title":"Oncol Lett"},{"key":"4289_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pharmthera.2019.05.012","volume":"201","author":"ML Stone","year":"2019","unstructured":"Stone ML, Beatty GL. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol Ther. 2019;201:202\u201313. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.05.012.","journal-title":"Pharmacol Ther"},{"key":"4289_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51:27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025.","journal-title":"Immunity"},{"key":"4289_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000046","volume":"6","author":"HC Harsha","year":"2009","unstructured":"Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009;6:e1000046. https:\/\/doi.org\/10.1371\/journal.pmed.1000046.","journal-title":"PLoS Med"},{"key":"4289_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1053\/j.gastro.2020.11.052","volume":"160","author":"JF Fahrmann","year":"2021","unstructured":"Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J, et al. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection. Gastroenterology. 2021;160:1373-1383.e1376. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.052.","journal-title":"Gastroenterology"},{"key":"4289_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13193-011-0042-1","volume":"2","author":"UK Ballehaninna","year":"2011","unstructured":"Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a biomarker for pancreatic cancer\u2014a comprehensive review. Ind J Surg Oncol. 2011;2:88\u2013100. https:\/\/doi.org\/10.1007\/s13193-011-0042-1.","journal-title":"Ind J Surg Oncol"},{"key":"4289_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1440-1746.2004.03219.x","volume":"19","author":"JE Kim","year":"2004","unstructured":"Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19:182\u20136. https:\/\/doi.org\/10.1111\/j.1440-1746.2004.03219.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"4289_CR44","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501. https:\/\/doi.org\/10.1038\/nature14169.","journal-title":"Nature"},{"key":"4289_CR45","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41416-022-01745-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz D, Sereni E, Lancelotti F, Pea A, Luchini C, Innamorati G, et al. Circulating tumour DNA: a challenging innovation to develop \u201cprecision onco-surgery\u201d in pancreatic adenocarcinoma. Br J Cancer. 2022;126:1676\u201383. https:\/\/doi.org\/10.1038\/s41416-022-01745-2.","journal-title":"Br J Cancer"},{"key":"4289_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1779-7","volume":"15","author":"J Earl","year":"2015","unstructured":"Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodr\u00edguez-Garrote M, et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797. https:\/\/doi.org\/10.1186\/s12885-015-1779-7.","journal-title":"BMC Cancer"},{"key":"4289_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra224. https:\/\/doi.org\/10.1126\/scitranslmed.3007094.","journal-title":"Sci Transl Med"},{"key":"4289_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987\u20131002. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.009.","journal-title":"Ann Oncol"},{"key":"4289_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejrad.2017.04.009","volume":"92","author":"J Toft","year":"2017","unstructured":"Toft J, Hadden WJ, Laurence JM, Lam V, Yuen L, Janssen A, et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: a systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol. 2017;92:17\u201323. https:\/\/doi.org\/10.1016\/j.ejrad.2017.04.009.","journal-title":"Eur J Radiol"},{"key":"4289_CR50","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.gie.2021.10.025","volume":"95","author":"TA Gonda","year":"2022","unstructured":"Gonda TA, Farrell J, Wallace M, Khanna L, Janec E, Kwon R, et al. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. Gastrointest Endosc. 2022;95:723-732.e727. https:\/\/doi.org\/10.1016\/j.gie.2021.10.025.","journal-title":"Gastrointest Endosc"},{"key":"4289_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3322\/caac.21626","volume":"70","author":"AJ Grossberg","year":"2020","unstructured":"Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70:375\u2013403. https:\/\/doi.org\/10.3322\/caac.21626.","journal-title":"CA Cancer J Clin"},{"key":"4289_CR52","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"key":"4289_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1402128","volume":"14","author":"SA Long","year":"2024","unstructured":"Long SA, Amparo AM, Goodhart G, Ahmad SA, Waters AM. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Front Oncol. 2024;14:1402128. https:\/\/doi.org\/10.3389\/fonc.2024.1402128.","journal-title":"Front Oncol"},{"key":"4289_CR54","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031435","author":"AM Waters","year":"2018","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018. https:\/\/doi.org\/10.1101\/cshperspect.a031435.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4289_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","volume":"42","author":"M Molina-Arcas","year":"2024","unstructured":"Molina-Arcas M, Downward J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell. 2024;42:338\u201357. https:\/\/doi.org\/10.1016\/j.ccell.2024.02.012.","journal-title":"Cancer Cell"},{"key":"4289_CR56","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.Mcr-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res. 2015;13:1325\u201335. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-15-0203.","journal-title":"Mol Cancer Res"},{"key":"4289_CR57","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351. https:\/\/doi.org\/10.1038\/nature12796.","journal-title":"Nature"},{"key":"4289_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1281545","volume":"13","author":"D Cheng","year":"2023","unstructured":"Cheng D, Hu J, Wu X, Wang B, Chen R, Zhao W, et al. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III\/IV pancreatic cancer: a retrospective real-world study. Front Oncol. 2023;13:1281545. https:\/\/doi.org\/10.3389\/fonc.2023.1281545.","journal-title":"Front Oncol"},{"key":"4289_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/00031348251393930","author":"E Jacobs","year":"2025","unstructured":"Jacobs E, Patil S, Mittal VK, Jacobs MJ. Incidence and outcomes of metastatic patterns of pancreatic ductal adenocarcinoma. Am Surg. 2025. https:\/\/doi.org\/10.1177\/00031348251393930.","journal-title":"Am Surg"},{"key":"4289_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2025-001925","author":"M Fivaz","year":"2025","unstructured":"Fivaz M, Bornand A, Corro C, Koessler T, Genoud V. Actionable mutations in pancreatic cancer: where targeted therapies are making a difference. BMJ Open Gastroenterol. 2025. https:\/\/doi.org\/10.1136\/bmjgast-2025-001925.","journal-title":"BMJ Open Gastroenterol"},{"key":"4289_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071246","author":"KL Liang","year":"2025","unstructured":"Liang KL, Azad NS. Immune-based strategies for pancreatic cancer in the adjuvant setting. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17071246.","journal-title":"Cancers"},{"key":"4289_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215510","author":"EM Anderson","year":"2021","unstructured":"Anderson EM, Thomassian S, Gong J, Hendifar A, Osipov A. Advances in pancreatic ductal adenocarcinoma treatment. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13215510.","journal-title":"Cancers"},{"key":"4289_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004485","author":"S Chakrabarti","year":"2022","unstructured":"Chakrabarti S, Bucheit L, Starr JS, Innis-Shelton R, Shergill A, Dada H, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004485.","journal-title":"J Immunother Cancer"},{"key":"4289_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1240859","volume":"5","author":"I Poschke","year":"2016","unstructured":"Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5:e1240859. https:\/\/doi.org\/10.1080\/2162402x.2016.1240859.","journal-title":"Oncoimmunology"},{"key":"4289_CR65","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"4289_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1345-6","volume":"14","author":"M Orth","year":"2019","unstructured":"Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14:141. https:\/\/doi.org\/10.1186\/s13014-019-1345-6.","journal-title":"Radiat Oncol"},{"key":"4289_CR67","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.Can-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057\u201369. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-3723.","journal-title":"Cancer Res"},{"key":"4289_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201034","volume":"33","author":"L Gross","year":"2025","unstructured":"Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, et al. TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. Mol Ther Oncol. 2025;33:201034. https:\/\/doi.org\/10.1016\/j.omton.2025.201034.","journal-title":"Mol Ther Oncol"},{"key":"4289_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17:40. https:\/\/doi.org\/10.1186\/s13045-024-01561-6.","journal-title":"J Hematol Oncol"},{"key":"4289_CR70","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.5114\/aoms.2019.84888","volume":"17","author":"GZ Zhang","year":"2021","unstructured":"Zhang GZ, Li TF, Han SY. Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors. Arch Med Sci AMS. 2021;17:1213\u201320. https:\/\/doi.org\/10.5114\/aoms.2019.84888.","journal-title":"Arch Med Sci AMS"},{"key":"4289_CR71","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334. https:\/\/doi.org\/10.1038\/s41591-024-03037-z.","journal-title":"Nat Med"},{"key":"4289_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Xu Z, Hu C, Zhang S, Zi M, Yuan L, et al. Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications. Front Oncol. 2023;13:1132319. https:\/\/doi.org\/10.3389\/fonc.2023.1132319.","journal-title":"Front Oncol"},{"key":"4289_CR73","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/bjc.2016.215","volume":"115","author":"NV Rajeshkumar","year":"2016","unstructured":"Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, et al. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer. 2016;115:442\u201353. https:\/\/doi.org\/10.1038\/bjc.2016.215.","journal-title":"Br J Cancer"},{"key":"4289_CR74","doi-asserted-by":"publisher","first-page":"19790","DOI":"10.1021\/acsnano.5c02099","volume":"19","author":"A Dubrova","year":"2025","unstructured":"Dubrova A, Cavaniol C, de Van Walle A, Mathieu P, Fusilier Z, Yaacoub N, et al. Magnetite nanoparticle photothermal therapy in a pancreatic tumor-on-chip: a dual-action approach targeting cancer cells and their microenvironment. ACS Nano. 2025;19:19790\u2013805. https:\/\/doi.org\/10.1021\/acsnano.5c02099.","journal-title":"ACS Nano"},{"key":"4289_CR75","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1021\/acsnano.3c12678","volume":"18","author":"J Liu","year":"2024","unstructured":"Liu J, Jiang X, Li Y, Yang K, Weichselbaum RR, Lin W. Immunogenic bifunctional nanoparticle suppresses programmed cell death-ligand 1 in cancer and dendritic cells to enhance adaptive immunity and chemo-immunotherapy. ACS Nano. 2024;18:5152\u201366. https:\/\/doi.org\/10.1021\/acsnano.3c12678.","journal-title":"ACS Nano"},{"key":"4289_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202005993","volume":"17","author":"X Liu","year":"2021","unstructured":"Liu X, Jiang J, Chang CH, Liao YP, Lodico JJ, Tang I, et al. Development of facile and versatile platinum drug delivering silicasome nanocarriers for efficient pancreatic cancer chemo-immunotherapy. Small (Weinheim an der Bergstrasse, Germany). 2021;17:e2005993. https:\/\/doi.org\/10.1002\/smll.202005993.","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"key":"4289_CR77","doi-asserted-by":"publisher","first-page":"9830","DOI":"10.1021\/acsnano.8b00967","volume":"12","author":"L Shen","year":"2018","unstructured":"Shen L, Li J, Liu Q, Song W, Zhang X, Tiruthani K, et al. Local blockade of interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers. ACS Nano. 2018;12:9830\u201341. https:\/\/doi.org\/10.1021\/acsnano.8b00967.","journal-title":"ACS Nano"},{"key":"4289_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04519-3","volume":"21","author":"H Qin","year":"2023","unstructured":"Qin H, Chen J, Bouchekioua-Bouzaghou K, Meng YM, Griera JB, Jiang X, et al. Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk. J Transl Med. 2023;21:702. https:\/\/doi.org\/10.1186\/s12967-023-04519-3.","journal-title":"J Transl Med"},{"key":"4289_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01914-8","volume":"4","author":"A Rosewell Shaw","year":"2021","unstructured":"Rosewell Shaw A, Porter CE, Yip T, Mah WC, McKenna MK, Dysthe M, et al. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021;4:368. https:\/\/doi.org\/10.1038\/s42003-021-01914-8.","journal-title":"Commun Biol"},{"key":"4289_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023;388:33\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2208470.","journal-title":"N Engl J Med"},{"key":"4289_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ph18121788","author":"FE Alanazi","year":"2025","unstructured":"Alanazi FE, Alatawi Y, Alattar A, Alshaman R, Kotb AA, Hetta HF. Broad-spectrum RAS inhibition in pancreatic ductal adenocarcinoma: mechanistic advances and therapeutic promise. Pharmaceuticals (Basel, Switzerland). 2025. https:\/\/doi.org\/10.3390\/ph18121788.","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"4289_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.976450","volume":"12","author":"JE Shin","year":"2022","unstructured":"Shin JE, An HJ, Park HS, Kim H, Shim BY. Efficacy of dabrafenib\/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: a case report. Front Oncol. 2022;12:976450. https:\/\/doi.org\/10.3389\/fonc.2022.976450.","journal-title":"Front Oncol"},{"key":"4289_CR83","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/1078-0432.Ccr-23-0983","volume":"30","author":"I Zhou","year":"2024","unstructured":"Zhou I, Plana D, Palmer AC. Tumor-specific activity of precision medicines in the NCI-MATCH trial. Clin Cancer Res. 2024;30:786\u201392. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0983.","journal-title":"Clin Cancer Res"},{"key":"4289_CR84","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.sjbs.2012.08.001","volume":"19","author":"A Ambesajir","year":"2012","unstructured":"Ambesajir A, Kaushik A, Kaushik JJ, Petros ST. RNA interference: a futuristic tool and its therapeutic applications. Saudi J Biol Sci. 2012;19:395\u2013403. https:\/\/doi.org\/10.1016\/j.sjbs.2012.08.001.","journal-title":"Saudi J Biol Sci"},{"key":"4289_CR85","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1124\/jpet.122.001234","volume":"384","author":"GM Traber","year":"2023","unstructured":"Traber GM, Yu A-M. Rnai-based therapeutics and novel RNA bioengineering technologies. J Pharmacol Exp Ther. 2023;384:133\u201354. https:\/\/doi.org\/10.1124\/jpet.122.001234.","journal-title":"J Pharmacol Exp Ther"},{"key":"4289_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17111502","author":"T Ren","year":"2025","unstructured":"Ren T, Ma L, Fu P, Zhang C. Nanoparticles used for the delivery of RNAi-based therapeutics. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17111502.","journal-title":"Pharmaceutics"},{"key":"4289_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab006","volume":"1","author":"Y Xing","year":"2021","unstructured":"Xing Y, Wang Z, Lu Z, Xia J, Xie Z, Jiao M, et al. MicroRNAs: immune modulators in cancer immunotherapy. Immunotherapy Advances. 2021;1:ltab006. https:\/\/doi.org\/10.1093\/immadv\/ltab006.","journal-title":"Immunotherapy Advances"},{"key":"4289_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-016-0842-4","volume":"14","author":"GY Hu","year":"2016","unstructured":"Hu GY, Tao F, Wang W, Ji KW. Prognostic value of microRNA-21 in pancreatic ductal adenocarcinoma: a meta-analysis. World J Surg Oncol. 2016;14:82. https:\/\/doi.org\/10.1186\/s12957-016-0842-4.","journal-title":"World J Surg Oncol"},{"key":"4289_CR89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.biomaterials.2019.02.016","volume":"201","author":"YE Seo","year":"2019","unstructured":"Seo YE, Suh HW, Bahal R, Josowitz A, Zhang J, Song E, et al. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials. 2019;201:87\u201398. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.02.016.","journal-title":"Biomaterials"},{"key":"4289_CR90","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020;18:2401\u201315. https:\/\/doi.org\/10.1016\/j.csbj.2020.08.031.","journal-title":"Comput Struct Biotechnol J"},{"key":"4289_CR91","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000875","author":"KM McAndrews","year":"2021","unstructured":"McAndrews KM, Xiao F, Chronopoulos A, LeBleu VS, Kugeratski FG, Kalluri R. Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer. Life Sci Alliance. 2021. https:\/\/doi.org\/10.26508\/lsa.202000875.","journal-title":"Life Sci Alliance"},{"key":"4289_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010137","author":"EJ Won","year":"2022","unstructured":"Won EJ, Park H, Yoon TJ, Cho YS. Gene therapy using nanocarriers for pancreatic ductal adenocarcinoma: applications and challenges in cancer therapeutics. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14010137.","journal-title":"Pharmaceutics"},{"key":"4289_CR93","doi-asserted-by":"crossref","unstructured":"Krithara A, Aisopos F, Rentoumi V, Nentidis A, Bougatiotis K, Vidal ME. et al. iASiS: towards heterogeneous big data analysis for personalized medicine. In: Proceedings of the 2019 IEEE 32nd international symposium on computer-based medical systems (CBMS), 5\u20137 June 2019, 2019;106-11.","DOI":"10.1109\/CBMS.2019.00032"},{"key":"4289_CR94","doi-asserted-by":"publisher","DOI":"10.2196\/44248","volume":"25","author":"Z Jan","year":"2023","unstructured":"Jan Z, El Assadi F, Abd-Alrazaq A, Jithesh PV. Artificial intelligence for the prediction and early diagnosis of pancreatic cancer: scoping review. J Med Internet Res. 2023;25:e44248. https:\/\/doi.org\/10.2196\/44248.","journal-title":"J Med Internet Res"},{"key":"4289_CR95","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/mog.0000000000000966","volume":"39","author":"L Yao","year":"2023","unstructured":"Yao L, Zhang Z, Keles E, Yazici C, Tirkes T, Bagci U. A review of deep learning and radiomics approaches for pancreatic cancer diagnosis from medical imaging. Curr Opin Gastroenterol. 2023;39:436\u201347. https:\/\/doi.org\/10.1097\/mog.0000000000000966.","journal-title":"Curr Opin Gastroenterol"},{"key":"4289_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164135","author":"N Lintern","year":"2023","unstructured":"Lintern N, Smith AM, Jayne DG, Khaled YS. Photodynamic stromal depletion in pancreatic ductal adenocarcinoma. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15164135.","journal-title":"Cancers"},{"key":"4289_CR97","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3748\/wjg.v24.i20.2137","volume":"24","author":"M Hilmi","year":"2018","unstructured":"Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: where are we now? World J Gastroenterol. 2018;24:2137\u201351. https:\/\/doi.org\/10.3748\/wjg.v24.i20.2137.","journal-title":"World J Gastroenterol"},{"key":"4289_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189484","volume":"1880","author":"J Zhang","year":"2025","unstructured":"Zhang J, Xiao L, Zhang Y, Jin G, Zheng K. AI-powered vaccine breakthroughs: targeting pancreatic cancer with neoantigens and combination therapies. Biochim Biophys Acta (BBA) Rev Cancer. 2025;1880:189484. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189484.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"key":"4289_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01258-y","volume":"10","author":"F Villanueva-Flores","year":"2025","unstructured":"Villanueva-Flores F, Sanchez-Villamil JI, Garcia-Atutxa I. AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development. NPJ Vaccines. 2025;10:207. https:\/\/doi.org\/10.1038\/s41541-025-01258-y.","journal-title":"NPJ Vaccines"},{"key":"4289_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56818-6","volume":"16","author":"M Pourmousa","year":"2025","unstructured":"Pourmousa M, Jain S, Barnaeva E, Jin W, Hochuli J, Itkin Z, et al. AI-driven discovery of synergistic drug combinations against pancreatic cancer. Nat Commun. 2025;16:4020. https:\/\/doi.org\/10.1038\/s41467-025-56818-6.","journal-title":"Nat Commun"},{"key":"4289_CR101","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1053\/j.gastro.2017.01.010","volume":"152","author":"S Endo","year":"2017","unstructured":"Endo S, Nakata K, Ohuchida K, Takesue S, Nakayama H, Abe T, et al. Autophagy is required for activation of pancreatic stellate cells, associated with pancreatic cancer progression and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017;152:1492-1506.e1424. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.010.","journal-title":"Gastroenterology"},{"key":"4289_CR102","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3892\/ijo.2016.3374","volume":"48","author":"K Horioka","year":"2016","unstructured":"Horioka K, Ohuchida K, Sada M, Zheng B, Moriyama T, Fujita H, et al. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. Int J Oncol. 2016;48:1499\u2013508. https:\/\/doi.org\/10.3892\/ijo.2016.3374.","journal-title":"Int J Oncol"},{"key":"4289_CR103","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.4161\/cbt.5.12.3354","volume":"5","author":"H Sugimoto","year":"2006","unstructured":"Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006;5:1640\u20136. https:\/\/doi.org\/10.4161\/cbt.5.12.3354.","journal-title":"Cancer Biol Ther"},{"key":"4289_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05674-x","volume":"22","author":"B Gao","year":"2024","unstructured":"Gao B, Hu G, Sun B, Li W, Yang H. BNIP3+ fibroblasts associated with hypoxia and inflammation predict prognosis and immunotherapy response in pancreatic ductal adenocarcinoma. J Transl Med. 2024;22:937. https:\/\/doi.org\/10.1186\/s12967-024-05674-x.","journal-title":"J Transl Med"},{"key":"4289_CR105","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-025-03299-5","volume":"134","author":"X Wang","year":"2026","unstructured":"Wang X, Shinjo K, Kumegawa K, Maruyama R, Mii S, Shiraki Y, et al. Transgelin defines pro-tumorigenic cancer-associated fibroblasts in pancreatic cancer. Br J Cancer. 2026;134:577\u201388. https:\/\/doi.org\/10.1038\/s41416-025-03299-5.","journal-title":"Br J Cancer"},{"key":"4289_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00233-8","volume":"5","author":"K Lv","year":"2024","unstructured":"Lv K, He T. Cancer-associated fibroblasts: heterogeneity, tumorigenicity and therapeutic targets. Mol Biomed. 2024;5:70. https:\/\/doi.org\/10.1186\/s43556-024-00233-8.","journal-title":"Mol Biomed"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04289-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:12Z","timestamp":1784975352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04289-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":106,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04289-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest, financial or otherwise.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this article, no human and animal subjects are used.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}